OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Separately, Evercore ISI reduced their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.38.

OraSure Technologies Stock Performance

NASDAQ:OSUR traded down $0.26 during trading hours on Thursday, hitting $5.05. The stock had a trading volume of 1,166,201 shares, compared to its average volume of 870,201. OraSure Technologies has a one year low of $4.38 and a one year high of $8.45. The company has a market cap of $385.99 million, a price-to-earnings ratio of 7.01 and a beta of 0.23. The business’s 50 day moving average is $6.03 and its 200-day moving average is $6.79.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share for the quarter, meeting the consensus estimate of $0.04. The company had revenue of $54.10 million during the quarter, compared to analysts’ expectations of $52.27 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The business’s quarterly revenue was down 65.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 earnings per share. On average, sell-side analysts anticipate that OraSure Technologies will post -0.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Trexquant Investment LP boosted its holdings in OraSure Technologies by 3.3% during the third quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock worth $383,000 after purchasing an additional 2,049 shares during the last quarter. Diversified Trust Co boosted its holdings in OraSure Technologies by 17.7% during the fourth quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 2,406 shares during the last quarter. AJOVista LLC acquired a new position in OraSure Technologies during the fourth quarter worth $39,000. Deutsche Bank AG lifted its stake in OraSure Technologies by 3.1% in the third quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after acquiring an additional 5,875 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in OraSure Technologies by 2.6% in the first quarter. Los Angeles Capital Management LLC now owns 341,125 shares of the medical instruments supplier’s stock valued at $2,098,000 after acquiring an additional 8,523 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.